Automated and closed solutions for autologous CAR T cell therapy manufacturing

Why should you increase the level of automation in your auto CAR T manufacturing process?

One of the main challenges of manufacturing autologous CAR T cell therapy is the cost. Open, manual operations are error- and contamination-prone. And if you’re thinking of scaling, the probability of these errors might just scale with you. But you can reduce the risk—while keeping flexibility—with closed and automated systems. Automation brings formerly discrete steps together, saving you time and money. Plus, by standardizing your process, you’re one step closer to meeting regulatory requirements—and to safely delivering your therapies to patients.

Contact us to learn more


Hover over the products below to learn more about the CAR T cell therapy workflow

Discover how Cytiva can support your development and production needs across a variety of molecules and therapeutics.

mRNA
mAbs
Viral vectors